1575 related articles for article (PubMed ID: 33510460)
41. Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities.
da Fonseca LG; Araujo RLC
World J Gastroenterol; 2022 Jul; 28(28):3573-3585. PubMed ID: 36161045
[TBL] [Abstract][Full Text] [Related]
42. Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma.
Dumolard L; Ghelfi J; Roth G; Decaens T; Macek Jilkova Z
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575734
[TBL] [Abstract][Full Text] [Related]
43. Thermal Ablation Versus Stereotactic Body Radiotherapy After Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.
Nabavizadeh N; Jahangiri Y; Rahmani R; Tomozawa Y; Geeratikun Y; Chen Y; Hung A; Degnin C; Farsad K
AJR Am J Roentgenol; 2021 Sep; 217(3):691-698. PubMed ID: 32997517
[No Abstract] [Full Text] [Related]
44. What Should Be the Rules for Downstaging for Hepatocellular Carcinoma?
Dirican A; Karakas S
J Gastrointest Cancer; 2020 Dec; 51(4):1148-1151. PubMed ID: 32839945
[TBL] [Abstract][Full Text] [Related]
45. Locoregional Therapies in the Treatment of 3- to 5-cm Hepatocellular Carcinoma: Critical Review of the Literature.
Young S; Golzarian J
AJR Am J Roentgenol; 2020 Jul; 215(1):223-234. PubMed ID: 32255691
[No Abstract] [Full Text] [Related]
46. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
Choi JY
Oncology; 2011; 81 Suppl 1():141-7. PubMed ID: 22212948
[TBL] [Abstract][Full Text] [Related]
47. Chemoembolization and bland embolization: a critical appraisal.
Befeler AS
Clin Liver Dis; 2005 May; 9(2):287-300, vii. PubMed ID: 15831274
[TBL] [Abstract][Full Text] [Related]
48. Role of locoregional therapies in the wake of systemic therapy.
Palmer DH; Malagari K; Kulik LM
J Hepatol; 2020 Feb; 72(2):277-287. PubMed ID: 31954492
[TBL] [Abstract][Full Text] [Related]
49. New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma.
Liu H; Wang C; Wang R; Cao H; Cao Y; Huang T; Lu Z; Xiao H; Hu M; Wang H; Zhao J
Chin J Cancer Res; 2024 Apr; 36(2):167-194. PubMed ID: 38751435
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic advances for patients with intermediate hepatocellular carcinoma.
Sun JY; Yin T; Zhang XY; Lu XJ
J Cell Physiol; 2019 Aug; 234(8):12116-12121. PubMed ID: 30648254
[TBL] [Abstract][Full Text] [Related]
51. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate.
Cescon M; Cucchetti A; Ravaioli M; Pinna AD
J Hepatol; 2013 Mar; 58(3):609-18. PubMed ID: 23041304
[TBL] [Abstract][Full Text] [Related]
52. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma.
Tsochatzis EA; Fatourou E; O'Beirne J; Meyer T; Burroughs AK
World J Gastroenterol; 2014 Mar; 20(12):3069-77. PubMed ID: 24695579
[TBL] [Abstract][Full Text] [Related]
53. Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma.
Delhaye C; Hendlisz A; Vouche M
Curr Opin Oncol; 2019 Jul; 31(4):339-345. PubMed ID: 30896451
[TBL] [Abstract][Full Text] [Related]
54. Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years?
Pillai AA; Ramanathan M; Kulik L
Clin Liver Dis; 2020 Nov; 24(4):681-700. PubMed ID: 33012453
[TBL] [Abstract][Full Text] [Related]
55. Radiofrequency vs Microwave Ablation After Neoadjuvant Transarterial Bland and Drug-Eluting Microsphere Chembolization for the Treatment of Hepatocellular Carcinoma.
Thornton LM; Cabrera R; Kapp M; Lazarowicz M; Vogel JD; Toskich BB
Curr Probl Diagn Radiol; 2017; 46(6):402-409. PubMed ID: 28392205
[TBL] [Abstract][Full Text] [Related]
56. Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3 cm.
Jacob R; Turley F; Redden DT; Saddekni S; Aal AK; Keene K; Yang E; Zarzour J; Bolus D; Smith JK; Gray S; White J; Eckhoff DE; DuBay DA
HPB (Oxford); 2015 Feb; 17(2):140-9. PubMed ID: 25186290
[TBL] [Abstract][Full Text] [Related]
57. Adjuvant therapy for hepatocellular carcinoma after curative treatment.
Jeng WJ; Lin CC; Chen WT; Sheen IS; Lin CY; Lin SM
Dig Dis; 2014; 32(6):747-54. PubMed ID: 25376293
[TBL] [Abstract][Full Text] [Related]
58. Interventional radiology for hepatocellular carcinoma.
Loffroy R
Minerva Gastroenterol Dietol; 2011 Sep; 57(3):299-309. PubMed ID: 21769079
[TBL] [Abstract][Full Text] [Related]
59. Newer treatments for advanced hepatocellular carcinoma.
Song MJ; Bae SH
Korean J Intern Med; 2014 Mar; 29(2):149-55. PubMed ID: 24648795
[TBL] [Abstract][Full Text] [Related]
60. Hepatocellular carcinoma downstaging in liver transplantation.
Yu CY; Ou HY; Huang TL; Chen TY; Tsang LL; Chen CL; Cheng YF
Transplant Proc; 2012 Mar; 44(2):412-4. PubMed ID: 22410030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
